Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs for Progressive and Refractory NMOSD
NCT02249676Phase 2Completed
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jan 2013
- Primary completion
- Dec 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous mesenchymal stem cells in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tianjin Medical University General Hospital. Started Jan 2013; status: completed.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT02249676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249676.